scholarly journals A novel anticancer agent SNG1153 inhibits growth of lung cancer stem/progenitor cells

Oncotarget ◽  
2016 ◽  
Vol 7 (29) ◽  
pp. 45158-45170 ◽  
Author(s):  
Shiyang Liu ◽  
Yuming Guo ◽  
Jing Wang ◽  
Hai Zhu ◽  
Yuqing Han ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Progenitor Cells ◽  
Anticancer Agent

Semi-synthesis and anti-lung cancer activity evaluation of aryl dihydrothiazol acyl podophyllotoxin ester derivatives

RSC Advances ◽  
2015 ◽  
Vol 5 (35) ◽  
pp. 27775-27784 ◽  
Author(s):  
Hong-Yan Lin ◽  
Li-Fei Bai ◽  
Fang Wang ◽  
Xun Wu ◽  
Lu-Jing Han ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Anticancer Agent ◽  
Tubulin Polymerization ◽  
Inhibition Effect ◽  
Activity Evaluation ◽  
Podophyllotoxin Derivatives ◽  
Cancer Activity

S12, the best anticancer agent among the 17 podophyllotoxin derivatives, showed a proliferative inhibition effect via inhibiting tubulin polymerization.

scholarly journals Intersections of lung progenitor cells, lung disease and lung cancer

2017 ◽  
Vol 26 (144) ◽  
pp. 170054 ◽  
Author(s):  
Carla F. Kim
Keyword(s):  
Lung Cancer ◽  
Progenitor Cells ◽  
Cell Biology ◽  
Progenitor Cell ◽  
Genetically Engineered ◽  
Response To Therapy ◽  
Culture Techniques ◽  
Genetically Engineered Mouse Models ◽  
Approaches To Study ◽  
Lung Progenitor

The use of stem cell biology approaches to study adult lung progenitor cells and lung cancer has brought a variety of new techniques to the field of lung biology and has elucidated new pathways that may be therapeutic targets in lung cancer. Recent results have begun to identify the ways in which different cell populations interact to regulate progenitor activity, and this has implications for the interventions that are possible in cancer and in a variety of lung diseases. Today's better understanding of the mechanisms that regulate lung progenitor cell self-renewal and differentiation, including understanding how multiple epigenetic factors affect lung injury repair, holds the promise for future better treatments for lung cancer and for optimising the response to therapy in lung cancer. Working between platforms in sophisticated organoid culture techniques, genetically engineered mouse models of injury and cancer, and human cell lines and specimens, lung progenitor cell studies can begin with basic biology, progress to translational research and finally lead to the beginnings of clinical trials.

P-947 The role of circulating endothelial progenitor cells in non-smallcell lung cancer

Lung Cancer ◽  
2005 ◽  
Vol 49 ◽  
pp. S368-S369
Author(s):  
B. Dome ◽  
J. Timar ◽  
G. Ostoros ◽  
L. Meszaros ◽  
J. Dobos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Endothelial Progenitor ◽  
Circulating Endothelial Progenitor Cells

scholarly journals Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Seung Yeob Hyun ◽  
Huong Thuy Le ◽  
Cong-Truong Nguyen ◽  
Young-Sik Yong ◽  
Hye-Jin Boo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Anticancer Agent ◽  
Hsp90 Inhibitor ◽  
Small Cell ◽  
Small Cell Lung

Prognostic impact of circulating endothelial cell counts in patients with advanced non-small cell lung cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e21045-e21045
Author(s):  
Nutan Jyothi DeJoubner ◽  
Hyunseok Kang ◽  
Qunna Li ◽  
Wayne A C Harris ◽  
Rena Stewart ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Small Cell Lung Cancer ◽  
Progenitor Cells ◽  
Advanced Nsclc ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cd4 Counts ◽  
Risk Of Death ◽  
Cell Counts

e21045 Background: Blood progenitor cells expressing the stem cell marker CD34 have been associated with prognosis in cancer. We hypothesized that non-small cell lung cancer (NSCLC) patients with higher numbers of circulating CD34+ endothelial progenitor cells (CD34+/CD146+/CD45-, CEC) would have worse post-treatment outcomes and patients with more hematopoietic progenitor cells (CD34+/CD45+/CD45dim/CD133+, HPC) would have better outcomes. Methods: Blood samples from patients with advanced NSCLC were analyzed at 3 time points: prior to chemotherapy, after cycle one, and at completion of treatment or progression of disease, in an IRB-approved protocol. CEC, HPC, and immune subsets were measured by flow cytometry optimized for rare event detection. Primary outcomes were progression and death from the time of study entry. Patients were categorized and compared for progression free survival (PFS) and overall survival (OS) based on median cell counts. Differences between groups were tested using log-rank test and Cox regression. Results: A total of 62 patients were enrolled with mean age of 64 (37-87 years). There were 29 deaths after a median follow-up of 8.1 months. 40 patients progressed at a median of 5.4 months. Median numbers of CEC, HPC, and CD4+ T-cells were (0.05/uL, 0.41/uL, and 637/uL, respectively). Lower CEC at baseline was associated with a favorable PFS compared to those with higher counts (median PFS of 7.3 months versus 4.3 months, p=0.049). In a multivariate analysis after adjusting for age, gender, smoking, race, TNM stage, pathology, performance status and CD4 counts at baseline, patients with high CEC had almost 3-fold risk of death (HR=2.70, p=0.04) and disease progression (HR=3.03, p < 0.01) compared with patients with low numbers of CEC. In the same model, patients with fewer CD4+ T cells had > 3 fold risk of death compared with patients with higher numbers (HR=3.79, p=0.01). HPC content was not associated with OS or PFS. Conclusions: In patients with advanced NSCLC, higher CEC and lower CD4 counts at diagnosis are associated with worse outcomes. Higher CEC may serve as a cellular biomarker for extent of disease or tumor biology. Patients with poor T-cell immunity prior to treatment have worse survival.

Sign in / Sign up

Export Citation Format

Share Document